ZURICH, Feb 11 (Reuters) - Novartis's Sandoz
generics division is buying GlaxoSmithKline's
cephalosporin antibiotics business that includes three brands
sold in more than 100 markets, it said on Thursday.
Sandoz will pay GSK $350 million at closing, plus additional
milestone payments of up to $150 million in the deal, which is
set to close in the second half of 2021, Novartis said. The
three brands Zinnat, Zinacef and Fortum had combined sales of
approximately $140 million in the relevant markets last year.
(Reporting by Michael Shields, editing by John Revill)